Widely used:Recently Viewed
Clear All
$240 Mln
--
0.63
--
0
-47.47 %
--
0 %
5.38
-2820805
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| -77.76 | 4.33 | -3.16 | -82.55 | -63.11 | -- | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| -24.78 | -76.04 | 61.84 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$239.63 Mln
$42.66 Mln
$0.00 Mln
$426.39 Mln
$44.03 Mln
High
$2.84 - 21.34
71,108,000
NASDAQ: ZNTL
New York, NY
https://zentalis.com
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a... protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. Read more
The total asset value of Zentalis Pharmaceuticals Inc (ZNTL) stood at $ 558 Mln as on 30-Jun-24
The share price of Zentalis Pharmaceuticals Inc (ZNTL) is $3.37 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Zentalis Pharmaceuticals Inc (ZNTL) has given a return of -63.11% in the last 3 years.
Zentalis Pharmaceuticals Inc (ZNTL) has a market capitalisation of $ 240 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Zentalis Pharmaceuticals Inc (ZNTL) is 0.63 times as on 04-Oct-2024, a 80% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Zentalis Pharmaceuticals Inc (ZNTL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zentalis Pharmaceuticals Inc (ZNTL) and enter the required number of quantities and click on buy to purchase the shares of Zentalis Pharmaceuticals Inc (ZNTL).
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
The CEO & director of Dr. Kimberly Lynn Blackwell M.D.. is Zentalis Pharmaceuticals Inc (ZNTL), and CFO & Sr. VP is Dr. Kimberly Lynn Blackwell M.D..
There is no promoter pledging in Zentalis Pharmaceuticals Inc (ZNTL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Zentalis Pharmaceuticals Inc. (ZNTL) | Ratios |
|---|---|
|
Return on equity(%)
|
-47.47
|
|
Operating margin(%)
|
-533.85
|
|
Net Margin(%)
|
-456.25
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Zentalis Pharmaceuticals Inc (ZNTL) was $0 Mln.
$0.17
